Cargando…

Blood pressure after PREeclampsia/HELLP by SELF monitoring (BP-PRESELF): rationale and design of a multicenter randomized controlled trial

BACKGROUND: Hypertensive disorders of pregnancy (HDP), such as preeclampsia (PE) or the Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) syndrome are associated with elevated cardiovascular disease (CVD) risks, but standardized prevention guidelines after such pregnancies are lacking. Hype...

Descripción completa

Detalles Bibliográficos
Autores principales: Muijsers, Hella E. C., van der Heijden, Olivier W. H., de Boer, Karin, van Bijsterveldt, Chantal, Buijs, Ciska, Pagels, Jens, Tönnies, Peter, Heiden, Susanne, Roeleveld, Nel, Maas, Angela H. E. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055029/
https://www.ncbi.nlm.nih.gov/pubmed/32131802
http://dx.doi.org/10.1186/s12905-020-00910-0
_version_ 1783503292863610880
author Muijsers, Hella E. C.
van der Heijden, Olivier W. H.
de Boer, Karin
van Bijsterveldt, Chantal
Buijs, Ciska
Pagels, Jens
Tönnies, Peter
Heiden, Susanne
Roeleveld, Nel
Maas, Angela H. E. M.
author_facet Muijsers, Hella E. C.
van der Heijden, Olivier W. H.
de Boer, Karin
van Bijsterveldt, Chantal
Buijs, Ciska
Pagels, Jens
Tönnies, Peter
Heiden, Susanne
Roeleveld, Nel
Maas, Angela H. E. M.
author_sort Muijsers, Hella E. C.
collection PubMed
description BACKGROUND: Hypertensive disorders of pregnancy (HDP), such as preeclampsia (PE) or the Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) syndrome are associated with elevated cardiovascular disease (CVD) risks, but standardized prevention guidelines after such pregnancies are lacking. Hypertension is the first emerging risk factor after PE/HELLP pregnancies and is a major risk factor for CVD. Hypertension before the age of 55 years may lead to various manifestations of end-organ damage at relatively young age. Therefore, timely treatment of elevated blood pressure is mandatory, but many of these high-risk women have long-term undetected and untreated hypertension before adequate treatment is initiated. AIM: The aim of our study is to assess whether home blood pressure monitoring (HBPM) in women with a previous PE/HELLP pregnancy is a valuable tool for the early detection of hypertension. METHODS: Women with a history of both early and late PE/HELLP syndrome aged 40–60 years are invited to participate. Patients with a history of CVD, known hypertension and/or use of antihypertensive medication are excluded. Women are randomized between HPBM or ‘usual care’. The primary outcome is feasibility and usability of HBPM after 1 year of follow-up. Secondary outcomes will be the effectiveness of HPBM to detect hypertension, the efficacy of BP treatment, quality of life, health-related symptoms, work ability, and life-style behaviour. The results of this study will provide better strategies for timely detection and prevention of hypertension in women after PE/HELLP. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03228082. Registered June 15, 2017.
format Online
Article
Text
id pubmed-7055029
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70550292020-03-10 Blood pressure after PREeclampsia/HELLP by SELF monitoring (BP-PRESELF): rationale and design of a multicenter randomized controlled trial Muijsers, Hella E. C. van der Heijden, Olivier W. H. de Boer, Karin van Bijsterveldt, Chantal Buijs, Ciska Pagels, Jens Tönnies, Peter Heiden, Susanne Roeleveld, Nel Maas, Angela H. E. M. BMC Womens Health Study Protocol BACKGROUND: Hypertensive disorders of pregnancy (HDP), such as preeclampsia (PE) or the Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) syndrome are associated with elevated cardiovascular disease (CVD) risks, but standardized prevention guidelines after such pregnancies are lacking. Hypertension is the first emerging risk factor after PE/HELLP pregnancies and is a major risk factor for CVD. Hypertension before the age of 55 years may lead to various manifestations of end-organ damage at relatively young age. Therefore, timely treatment of elevated blood pressure is mandatory, but many of these high-risk women have long-term undetected and untreated hypertension before adequate treatment is initiated. AIM: The aim of our study is to assess whether home blood pressure monitoring (HBPM) in women with a previous PE/HELLP pregnancy is a valuable tool for the early detection of hypertension. METHODS: Women with a history of both early and late PE/HELLP syndrome aged 40–60 years are invited to participate. Patients with a history of CVD, known hypertension and/or use of antihypertensive medication are excluded. Women are randomized between HPBM or ‘usual care’. The primary outcome is feasibility and usability of HBPM after 1 year of follow-up. Secondary outcomes will be the effectiveness of HPBM to detect hypertension, the efficacy of BP treatment, quality of life, health-related symptoms, work ability, and life-style behaviour. The results of this study will provide better strategies for timely detection and prevention of hypertension in women after PE/HELLP. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03228082. Registered June 15, 2017. BioMed Central 2020-03-04 /pmc/articles/PMC7055029/ /pubmed/32131802 http://dx.doi.org/10.1186/s12905-020-00910-0 Text en © The Author(s) 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Muijsers, Hella E. C.
van der Heijden, Olivier W. H.
de Boer, Karin
van Bijsterveldt, Chantal
Buijs, Ciska
Pagels, Jens
Tönnies, Peter
Heiden, Susanne
Roeleveld, Nel
Maas, Angela H. E. M.
Blood pressure after PREeclampsia/HELLP by SELF monitoring (BP-PRESELF): rationale and design of a multicenter randomized controlled trial
title Blood pressure after PREeclampsia/HELLP by SELF monitoring (BP-PRESELF): rationale and design of a multicenter randomized controlled trial
title_full Blood pressure after PREeclampsia/HELLP by SELF monitoring (BP-PRESELF): rationale and design of a multicenter randomized controlled trial
title_fullStr Blood pressure after PREeclampsia/HELLP by SELF monitoring (BP-PRESELF): rationale and design of a multicenter randomized controlled trial
title_full_unstemmed Blood pressure after PREeclampsia/HELLP by SELF monitoring (BP-PRESELF): rationale and design of a multicenter randomized controlled trial
title_short Blood pressure after PREeclampsia/HELLP by SELF monitoring (BP-PRESELF): rationale and design of a multicenter randomized controlled trial
title_sort blood pressure after preeclampsia/hellp by self monitoring (bp-preself): rationale and design of a multicenter randomized controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055029/
https://www.ncbi.nlm.nih.gov/pubmed/32131802
http://dx.doi.org/10.1186/s12905-020-00910-0
work_keys_str_mv AT muijsershellaec bloodpressureafterpreeclampsiahellpbyselfmonitoringbppreselfrationaleanddesignofamulticenterrandomizedcontrolledtrial
AT vanderheijdenolivierwh bloodpressureafterpreeclampsiahellpbyselfmonitoringbppreselfrationaleanddesignofamulticenterrandomizedcontrolledtrial
AT deboerkarin bloodpressureafterpreeclampsiahellpbyselfmonitoringbppreselfrationaleanddesignofamulticenterrandomizedcontrolledtrial
AT vanbijsterveldtchantal bloodpressureafterpreeclampsiahellpbyselfmonitoringbppreselfrationaleanddesignofamulticenterrandomizedcontrolledtrial
AT buijsciska bloodpressureafterpreeclampsiahellpbyselfmonitoringbppreselfrationaleanddesignofamulticenterrandomizedcontrolledtrial
AT pagelsjens bloodpressureafterpreeclampsiahellpbyselfmonitoringbppreselfrationaleanddesignofamulticenterrandomizedcontrolledtrial
AT tonniespeter bloodpressureafterpreeclampsiahellpbyselfmonitoringbppreselfrationaleanddesignofamulticenterrandomizedcontrolledtrial
AT heidensusanne bloodpressureafterpreeclampsiahellpbyselfmonitoringbppreselfrationaleanddesignofamulticenterrandomizedcontrolledtrial
AT roeleveldnel bloodpressureafterpreeclampsiahellpbyselfmonitoringbppreselfrationaleanddesignofamulticenterrandomizedcontrolledtrial
AT maasangelahem bloodpressureafterpreeclampsiahellpbyselfmonitoringbppreselfrationaleanddesignofamulticenterrandomizedcontrolledtrial